Brief: Idorsia Presents Results With Daridorexant In Children And Adolescents With Insomnia
23/10/2026 16:52
BRIEF-Idorsia Presents Results With Daridorexant In Children And Adolescents With Insomnia Oct 23 (Reuters) - IDORSIA LTD IDIA.S:
PRESENTS OUTSTANDING RESULTS WITH DARIDOREXANT IN CHILDREN AND ADOLESCENTS WITH INSOMNIA AND AN EXPANDING BODY OF EVIDENCE IN ADULTS AT SLEEP EUROPE 2026
A SINGLE 50 MG DOSE INCREASED SLEEP TIME BY 50 MINUTES OVERALL AND 64 MINUTES IN CHILDREN WITH NEURODEVELOPMENTAL DISORDERS, MOVING PARTICIPANTS CLOSER TO THEIR RECOMMENDED AGE‑APPROPRIATE SLEEP DURATION
DARIDOREXANT WAS WELL TOLERATED ACROSS DOSES INCLUDING 50 MG, HIGHEST RECOMMENDED DOSE FOR ADULTS, WITH A PEDIATRIC SAFETY PROFILE CONSISTENT WITH ESTABLISHED ADULT EVIDENCE
Source text: ID:nGNE3Ymjx4
Further company coverage: IDIA.S
(Gdansk Newsroom)
((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));;))